Drug Guide
Stavudine
Classification
Therapeutic: Antiretroviral agent
Pharmacological: Nucleoside reverse transcriptase inhibitor (NRTI)
FDA Approved Indications
- Treatment of HIV-1 infection in combination with other antiretroviral agents
Mechanism of Action
Stavudine is a nucleoside analogue that inhibits the activity of reverse transcriptase, an enzyme critical for the replication of HIV, thereby preventing the replication of the virus.
Dosage and Administration
Adult: Typically 40 mg orally twice daily; dose adjustments may be required in renal impairment.
Pediatric: Dosage based on weight and age, usually 0.75 mg/kg twice daily.
Geriatric: Dose adjustments may be necessary due to renal function; monitor closely.
Renal Impairment: Reduce dosage based on creatinine clearance, and monitor renal function.
Hepatic Impairment: Use with caution; no specific dose adjustment recommended.
Pharmacokinetics
Absorption: Well absorbed orally.
Distribution: Widely distributed in body tissues.
Metabolism: Primarily metabolized via phosphorylation; minimal hepatic metabolism.
Excretion: Excreted mainly via the kidneys.
Half Life: Approximately 1.5 to 3 hours.
Contraindications
- Hypersensitivity to Stavudine or any component of the formulation.
Precautions
- Lactic acidosis and severe hepatomegaly with steatosis have been reported, especially in women. Monitor for mitochondrial toxicity, peripheral neuropathy, pancreatitis, and lipodystrophy. Use caution in patients with renal impairment.
Adverse Reactions - Common
- Nausea (frequent)
- Peripheral neuropathy (frequent)
- Nausea and rash (frequent)
Adverse Reactions - Serious
- Lactic acidosis (rare but serious)
- Pancreatitis (rare)
- Hepatomegaly with steatosis (rare)
- Peripheral neuropathy leading to disability (rare)
Drug-Drug Interactions
- Didanosine (increased risk of peripheral neuropathy and pancreatitis)
- St. John’s wort (may decrease Stavudine levels)
Drug-Food Interactions
N/ADrug-Herb Interactions
N/ANursing Implications
Assessment: Monitor for signs of peripheral neuropathy, pancreatitis, lactic acidosis, and hepatotoxicity. Regular renal function tests are necessary.
Diagnoses:
- Impaired peripheral sensory perception
- Risk for lactic acidosis
Implementation: Administer with food to reduce gastrointestinal upset. Educate patients about potential side effects and the importance of adhering to prescribed doses.
Evaluation: Evaluate for effectiveness of viral suppression through lab tests and monitor for adverse effects.
Patient/Family Teaching
- Take medication exactly as prescribed.
- Report symptoms like unusual numbness/tingling, abdominal pain, or signs of lactic acidosis.
- Avoid alcohol and hepatotoxic substances.
- Attend regular lab visits for monitoring.
Special Considerations
Black Box Warnings:
- Lactic acidosis and severe hepatomegaly
Genetic Factors: None specified.
Lab Test Interference: May cause elevated serum amylase levels; monitor as clinically indicated.
Overdose Management
Signs/Symptoms: Nausea, vomiting, fatigue, lactic acidosis, and peripheral neuropathy.
Treatment: Supportive care, monitor acid-base status, and provide symptomatic treatment. Hemodialysis may be considered in overdose to remove Stavudine.
Storage and Handling
Storage: Store at room temperature between 20°C to 25°C (68°F to 77°F).
Stability: Stable under recommended storage conditions.